Markku Anttila

1.7k total citations
41 papers, 1.4k citations indexed

About

Markku Anttila is a scholar working on Pharmacology, Oncology and Pharmacology. According to data from OpenAlex, Markku Anttila has authored 41 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 8 papers in Oncology and 7 papers in Pharmacology. Recurrent topics in Markku Anttila's work include Pharmacogenetics and Drug Metabolism (14 papers), Estrogen and related hormone effects (7 papers) and Analytical Chemistry and Chromatography (5 papers). Markku Anttila is often cited by papers focused on Pharmacogenetics and Drug Metabolism (14 papers), Estrogen and related hormone effects (7 papers) and Analytical Chemistry and Chromatography (5 papers). Markku Anttila collaborates with scholars based in Finland, United Kingdom and Sweden. Markku Anttila's co-authors include Harry Scheinin, Antti Helminen, Lauri Vuorilehto, Jani Penttilä, Esa Heinonen, Hannu Sundquist, Risto Lammintausta, Leena Nyman, Eero A. Sotaniemi and Sakari Karhuvaara and has published in prestigious journals such as Anesthesiology, International Journal of Pharmaceutics and Life Sciences.

In The Last Decade

Markku Anttila

40 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markku Anttila Finland 22 390 273 213 194 175 41 1.4k
Ann Locniskar United States 17 514 1.3× 343 1.3× 251 1.2× 110 0.6× 235 1.3× 39 1.6k
Thomas K. Henthorn United States 28 701 1.8× 207 0.8× 423 2.0× 196 1.0× 132 0.8× 86 2.0k
Jay Ham United States 8 492 1.3× 141 0.5× 296 1.4× 145 0.7× 89 0.5× 12 1.3k
Max T. Baker United States 17 281 0.7× 142 0.5× 100 0.5× 140 0.7× 61 0.3× 50 1.3k
Felipe Sánchez de la Cuesta Spain 25 205 0.5× 421 1.5× 269 1.3× 144 0.7× 35 0.2× 105 2.2k
Yukio Horai Japan 17 210 0.5× 366 1.3× 355 1.7× 83 0.4× 35 0.2× 35 1.3k
France Varin Canada 26 721 1.8× 113 0.4× 332 1.6× 121 0.6× 110 0.6× 103 2.2k
Burnell R. Brown United States 20 502 1.3× 171 0.6× 107 0.5× 322 1.7× 89 0.5× 71 1.4k
David L. Roerig United States 24 339 0.9× 100 0.4× 107 0.5× 79 0.4× 53 0.3× 92 1.7k
Edmund Grześkowiak Poland 15 188 0.5× 130 0.5× 166 0.8× 75 0.4× 69 0.4× 126 968

Countries citing papers authored by Markku Anttila

Since Specialization
Citations

This map shows the geographic impact of Markku Anttila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markku Anttila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markku Anttila more than expected).

Fields of papers citing papers by Markku Anttila

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markku Anttila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markku Anttila. The network helps show where Markku Anttila may publish in the future.

Co-authorship network of co-authors of Markku Anttila

This figure shows the co-authorship network connecting the top 25 collaborators of Markku Anttila. A scholar is included among the top collaborators of Markku Anttila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markku Anttila. Markku Anttila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Penttilä, Jani, Antti Helminen, Markku Anttila, Susanna Hinkka‐Yli‐Salomäki, & Harry Scheinin. (2004). Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Canadian Journal of Physiology and Pharmacology. 82(5). 359–362. 60 indexed citations
2.
Horváth, Viola, et al.. (2004). Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. European Journal of Pharmaceutics and Biopharmaceutics. 58(3). 689–695. 5 indexed citations
3.
Huupponen, Risto, et al.. (2003). Pharmacokinetics of Deramciclane, a???Novel Anxiolytic Agent, after Intravenous and Oral Administration. Drugs in R&D. 4(6). 339–345. 1 indexed citations
4.
Anttila, Markku, et al.. (2002). Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European Journal of Clinical Pharmacology. 58(4). 259–263. 8 indexed citations
5.
Anttila, Markku, et al.. (2000). Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding. Clinical Neuropharmacology. 23(1). 22–27. 26 indexed citations
6.
Taavitsainen, Päivi, et al.. (2000). Selegiline Metabolism and Cytochrome P450 Enzymes:In vitro Study in Human Liver Microsomes*. Pharmacology & Toxicology. 86(5). 215–221. 46 indexed citations
7.
Laine, Kari, et al.. (1999). Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. British Journal of Clinical Pharmacology. 47(3). 249–254. 39 indexed citations
8.
Scheinin, Harry, Markku Anttila, Marja-Liisa Dahl, et al.. (1998). CYP2D6 polymorphism is not crucial for the disposition of selegiline*. Clinical Pharmacology & Therapeutics. 64(4). 402–411. 23 indexed citations
9.
Heinonen, Esa, Markku Anttila, Leena Nyman, et al.. (1997). Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans. The Journal of Clinical Pharmacology. 37(7). 602–609. 22 indexed citations
10.
Sotaniemi, Eero A. & Markku Anttila. (1997). Influence of age on toremifene pharmacokinetics. Cancer Chemotherapy and Pharmacology. 40(2). 185–188. 11 indexed citations
11.
Laine, Kari, Markku Anttila, Esa Heinonen, et al.. (1997). Lack of Adverse Interactions Between Concomitantly Administered Selegiline and Citalopram. Clinical Neuropharmacology. 20(5). 419–433. 46 indexed citations
12.
Gershanovich, M., et al.. (1997). High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemotherapy and Pharmacology. 39(6). 547–551. 11 indexed citations
13.
Liippo, Kari, Juha Ellmén, E Vänttinen, & Markku Anttila. (1996). Toremifene concentration and multidrug resistance in lung tumors. Cancer Chemotherapy and Pharmacology. 39(3). 212–216. 6 indexed citations
14.
Huupponen, Risto, Sakari Karhuvaara, Markku Anttila, Lauri Vuorilehto, & Harry Scheinin. (1995). Buccal delivery of an α2-adrenergic receptor antagonist, atipamezole, in humans*. Clinical Pharmacology & Therapeutics. 58(5). 506–511. 8 indexed citations
15.
Anttila, Markku, et al.. (1995). Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clinical Pharmacology & Therapeutics. 57(6). 628–635. 25 indexed citations
16.
Heinonen, Esa, Markku Anttila, & Risto Lammintausta. (1994). Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites*. Clinical Pharmacology & Therapeutics. 56(6 Pt 2). 742–749. 96 indexed citations
17.
Scheinin, Harry, Sakari Karhuvaara, Klaus T. Olkkola, et al.. (1992). Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clinical Pharmacology & Therapeutics. 52(5). 537–546. 63 indexed citations
18.
Laakso, Sirpa, Mika Scheinin, & Markku Anttila. (1990). Determination of erythromycin base and 2′-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 526(2). 475–486. 39 indexed citations
19.
Sipilä, Hannu, et al.. (1990). Metabolism of toremifene in the rat. Journal of Steroid Biochemistry. 36(3). 211–215. 25 indexed citations
20.
Sipilä, Hannu, et al.. (1988). Binding of Toremifene to Human Serum Proteins. Pharmacology & Toxicology. 63(1). 62–64. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann Locniskar Breakdown of academic impact, for papers by Thomas K. Henthorn Breakdown of academic impact, for papers by Jay Ham Breakdown of academic impact, for papers by Max T. Baker Breakdown of academic impact, for papers by Felipe Sánchez de la Cuesta Breakdown of academic impact, for papers by Yukio Horai Breakdown of academic impact, for papers by France Varin Breakdown of academic impact, for papers by Burnell R. Brown Breakdown of academic impact, for papers by David L. Roerig Breakdown of academic impact, for papers by Edmund Grześkowiak
Rankless by CCL
2026